Journal of Cutaneous and Aesthetic Surgery

: 2011  |  Volume : 4  |  Issue : 2  |  Page : 154--155

Eccrine hidrocystoma successfully treated with topical synthetic botulinum peptide

Vijay Gandhi, Geetanjali Naik, Prashant Verma 
 Department of Dermatology and STD, University College of Medical Sciences and Associated Guru Teg Bahadur Hospital, Shahadara, Delhi, India

Correspondence Address:
Vijay Gandhi
Department of Dermatology and STD, University College of Medical Sciences and Associated Guru Teg Bahadur Hospital, Shahadara, Delhi

How to cite this article:
Gandhi V, Naik G, Verma P. Eccrine hidrocystoma successfully treated with topical synthetic botulinum peptide.J Cutan Aesthet Surg 2011;4:154-155

How to cite this URL:
Gandhi V, Naik G, Verma P. Eccrine hidrocystoma successfully treated with topical synthetic botulinum peptide. J Cutan Aesthet Surg [serial online] 2011 [cited 2022 Aug 9 ];4:154-155
Available from:

Full Text


Eccrine hidrocystomas (EHs) are benign cystic lesions of eccrine ducts that are associated with a chronic course and seasonal variations. They are more frequent in females than in males. [1] Solitary EH can be treated easily by surgical excision; however, the treatment of multiple lesions is problematic. We report a case of multiple eccrine hydrocystomas over the face, which responded completely after 4 weeks of treatment with topical Botulinum Toxin (Boxtlak-BL) like preparation.

A 60-year-old Indian lady presented with multiple papules over the cheeks since last 5-6 years, which were persistent and aggravated in summer and on exposure to heat. On local examination, there were shiny, translucent papules of 1-3 mm in diameter on the centrofacial area. On puncturing with a disposable needle, clear watery fluid came out. A skin biopsy stained with haematoxylin and eosin showed dilated cystic spaces in upper dermis [Figure 1], which were unilocular and lined by flattened squamous epithelial cells in two layers. There were no myoepithelial cells in the cyst wall. There was no evidence of decapitation secretions in the lining cells. [2] Based on clinical features and histopathology, a diagnosis of multiple EHs was made. The patient was treated with topical Boxtlak-BL twice daily and there was almost complete clearance of lesions after 4 weeks of treatment [Figure 2] and [Figure 3].{Figure 1}{Figure 2}{Figure 3}

EH is a benign cystic condition of eccrine sweat ducts. [3] The aetiopathogenesis is still debatable. Electron microscopy has established that the cyst wall is composed of ductal cells. It is likely that obstruction of eccrine duct leads to retention of sweat causing flattening of the lining cells and cystic dilatation.

Treatment of EH is recommended for cosmetic reasons. Different modalities have been proposed with variable results, which include puncture and drainage of the cyst that gives transient improvement with an early recurrence, [4] surgical excision, [4] microdermabrasion and electrodessication with high risk of scarring, [5] pulse dye laser, [6] topical atropine [7] and scopolamine. [8] Recently EH has been treated with botulinum toxin (injectable) with good results. [9]

Botulinum toxin (Boxtlak-BL) is a potent neurotoxin that blocks cholinergic nerve terminals. It has been used in the treatment of blepharospasm, strabismus, torticollis, hemifacial spasm and other dystonias. [10] It has also been used in the treatment of hyperhidrosis [11] and facial wrinkles. Boxtlak-BL containing BoNT_L peptide significantly inhibits SNAP-25 (synaptosome-associated protein of 25 kd) [12] of SNARE complex thereby inhibiting the release of acetylcholine from vesicle within the cytoplasm of the motor nerve endings. The end result is chemodenervation of cholinergic nerves targeting the autonomic control of eccrine sweat glands.

We propose topical Botulinum toxin like peptide as a painless, non-invasive, cost-effective and safe technique for the treatment of multiple EH with excellent results.


1Hashimoto K, Lever WF. Tumors of skin appendages. In: Fitzpatrick TB, Eisen AZ, Wolf K Freedberg IM, Austen K. Dermatology in General Medicine. 4 th ed. New york: Mc Graw-Hill; 1983. p. 550-1.
2Klein W, Chan E, Seykora JT. Tumours of epidermal appendages. In: Eldn DE, editor. Levers histopathology of skin. 9 th ed. Philadelphia USA; Lippincott Williams and Wilkins; 2005. p. 867-926.
3Robinson AR. Hidrocystoma. J Cutan Genitourinary Dis 1893;11:292-303.
4Fariña MC, Piqué E, Olivares M, Escalonilla P, Martín L, Requena L, et al. Multiple hidrocystomas of face; Three cases. Clin Exp Dermatol 1995;20:323-7.
5Blugerman G, Sehavelzon D, D'Angelo S. Multiple eccrine hidrocystomas, A new therapeutic option with Botulinum Toxin. Dermatol Surg 2003;29:557-9.
6Tanzi E, Alster TS. Pulsed dye laser treatment of multiple eccrine hidrocystomas: A novel approach. Dermatol Surg 2001;27:898-900.
7Khunger N, Mishra S, Jain RK, Saxena S. Multiple eccrine hidrocystomas. Report of 2 cases treated unsuccessfully with atropine ointment. Indian J Dermatol Venereol Leprol 2004;70:367-9.
8Clever HW, Shal WJ. Multiple eccrine Hidrocystomas: A nonsurgical treatment. Arch Dermatol 1991;127:422-4.
9Correia O, Duarte A, Barros A, Rocha N. Multiple Eccrine Hidrocystomas- From Diagnosis to Treatment: The role of Dermatoscopy and Botulinum Toxin: Dermatology 2009;219:77-9.
10Carruthers A, Carruthers J. History of cosmetic use of Botulinum A exotoxin. Dermatol Surg 1998;24:1168-70.
11Glogou RG. Use of hyperhidrosis with botulinum toxin. Dermatol Clin 2004;22:177-85,vii.
12Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol 2001;248:3-10.